{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:52:12Z","timestamp":1790787132047,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The Immunosuppressant Bayesian Dose Adjustment web site aids clinicians and pharmacologists involved in the care of transplant recipients; it proposes dose adjustments based on the estimated area under the concentration\u2013time curve (AUCs). Three concentrations (T<jats:sub>20 min<\/jats:sub>, T<jats:sub>1 h<\/jats:sub>, and T<jats:sub>3 h<\/jats:sub>) are sufficient to estimate mycophenolic acid (MPA) AUC<jats:sub>0\u201312 h<\/jats:sub> in pediatric kidney transplant recipients. This study investigates mycophenolate mofetil (MMF) doses and MPA AUC values in pediatric kidney transplant recipients, and target exposure attainment when the proposed doses were followed, through a large-scale analysis of the data set collated since the inception of the Immunosuppressant Bayesian Dose Adjustment web site.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this study, 4051 MMF dose adjustment requests, corresponding to 1051 patients aged 0\u201318 years, were retrospectively analyzed. AUC calculations were performed in the back office of the Immunosuppressant Bayesian Dose Adjustment using published Bayesian and population pharmacokinetic models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The first AUC request was posted &gt;12 months posttransplantation for 41% of patients. Overall, only 50% had the first MPA AUC<jats:sub>0\u201312 h<\/jats:sub> within the recommended 30\u201360 mg.h\/L range. When the proposed dose was not followed, the proportion of patients with an AUC in the therapeutic range for MMF with cyclosporine or tacrolimus at the subsequent request was lower (40% and 45%, respectively) than when it was followed (58% and 60%, respectively): <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.08 and 0.006, respectively. Furthermore, 3 months posttransplantation, the dispersion of AUC values was often lower at the second visit when the proposed doses were followed, namely, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03, 0.003, and 0.07 in the 4 months\u20131 year, and beyond 1 year with &lt;6-month or &gt;6-month periods between both visits, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Owing to extreme interindividual variability in MPA exposure, MMF dose adjustment is necessary; it is efficient at reducing such variability when based on MPA AUC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001087","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T05:00:23Z","timestamp":1677214823000},"page":"591-598","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-8904","authenticated-orcid":false,"given":"Marc","family":"Labriffe","sequence":"first","affiliation":[{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges ; and"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Micallef","sequence":"additional","affiliation":[{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges ; and"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges ; and"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Saint-Marcoux","sequence":"additional","affiliation":[{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges ; and"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Debord","sequence":"additional","affiliation":[{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges ; and"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges ; and"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.phrs.2015.07.012","article-title":"Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients","volume":"99","author":"Woillard","year":"2015","journal-title":"Pharmacol Res."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trre.2010.06.001","article-title":"Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure","volume":"25","author":"Tett","year":"2011","journal-title":"Transplant Rev."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":"A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0b013e3181744199","article-title":"Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review","volume":"85","author":"Knight","year":"2008","journal-title":"Transplantation"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2125.2009.03612.x","article-title":"Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients","volume":"69","author":"Sommerer","year":"2010","journal-title":"Br J Clin Pharmacol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.clinthera.2008.04.014","article-title":"Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients","volume":"30","author":"Kuypers","year":"2008","journal-title":"Clin Ther."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","article-title":"A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil","volume":"44","author":"Pr\u00e9maud","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.phrs.2010.10.017","article-title":"Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches","volume":"63","author":"Pr\u00e9maud","year":"2011","journal-title":"Pharmacol Res."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","article-title":"Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods","volume":"27","author":"Pr\u00e9maud","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FTD.0b013e318285e779","article-title":"Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure","volume":"35","author":"Saint-Marcoux","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/FTD.0b013e31821633a6","article-title":"Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients","volume":"33","author":"Saint-Marcoux","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/FTD.0000000000000052","article-title":"Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data","volume":"36","author":"Trkulja","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00007691-200110000-00003","article-title":"Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients","volume":"23","author":"Filler","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2021.06.036","article-title":"How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not","volume":"100","author":"van Gelder","year":"2021","journal-title":"Kidney Int."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10157-012-0713-4","article-title":"A single daily dose enhances the adherence to immunosuppressive treatment in kidney transplant recipients: a cross-sectional study","volume":"17","author":"Obi","year":"2013","journal-title":"Clin Exp Nephrol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/TP.0000000000001372","article-title":"Age-dependent risk of graft failure in young kidney transplant recipients","volume":"101","author":"Kabor\u00e9","year":"2017","journal-title":"Transplantation"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/TP.0b013e31823411d7","article-title":"Association between age and graft failure rates in young kidney transplant recipients","volume":"92","author":"Foster","year":"2011","journal-title":"Transplantation"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1034\/j.1399-3046.149.ptr1s077.1.x","article-title":"Non-compliance and its management in teenagers","volume":"6","author":"Nevins","year":"2002","journal-title":"Pediatr Transplant."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1399-3046.2010.01299.x","article-title":"Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review","volume":"14","author":"Dobbels","year":"2009","journal-title":"Pediatr Transplant."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/FTD.0000000000000828","article-title":"Tacrolimus bayesian dose adjustment in pediatric renal transplant recipients","volume":"43","author":"Marquet","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.V133759","article-title":"The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy","volume":"13","author":"Weber","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s004670050020","article-title":"Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children","volume":"14","author":"Jacqz-Aigrain","year":"2000","journal-title":"Pediatr Nephrol."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00467-002-1057-1","article-title":"Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation","volume":"18","author":"David-Neto","year":"2003","journal-title":"Pediatr Nephrol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:17:10Z","timestamp":1748971030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001087","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"2022-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}